# Celldex Therapeutics (CLDX) — Analyst Forecast

CLDX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cldx/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 14 | 1 | 0 | 15 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $53.00 | $70.75 | $100.00 | 8 |

Last price $28.93 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 2, 2026 | HC Wainwright & Co. | Maintained | Buy | $64.00 |
| Sep 23, 2026 | Morgan Stanley | Maintained | Overweight | $57.00 |
| Sep 23, 2026 | Leerink Partners | Maintained | Outperform | $88.00 |
| Sep 22, 2026 | Cantor Fitzgerald | Maintained | Overweight | $72.00 |
| Sep 22, 2026 | HC Wainwright & Co. | Maintained | Buy | $64.00 |
| Sep 10, 2026 | Morgan Stanley | Maintained | Overweight | $50.00 |
| Aug 7, 2026 | Barclays | Maintained | Overweight | $53.00 |
| Aug 7, 2026 | Morgan Stanley | Maintained | Overweight | $46.00 |
| Jul 29, 2026 | Wells Fargo | Maintained | Overweight | $72.00 |
| Jul 22, 2026 | Canaccord Genuity | Maintained | Buy | $60.00 |
| Jul 22, 2026 | Cantor Fitzgerald | Maintained | Overweight | $61.00 |
| Jul 22, 2026 | Morgan Stanley | Maintained | Overweight | $40.00 |
| Jul 22, 2026 | Wells Fargo | Maintained | Overweight | $48.00 |
| Jul 20, 2026 | Guggenheim | Maintained | Buy | $100.00 |
| Jun 15, 2026 | HC Wainwright & Co. | Maintained | Buy | $42.00 |
| Jun 10, 2026 | UBS | Maintained | Buy | $45.00 |
| May 13, 2026 | Wells Fargo | Maintained | Overweight | $54.00 |
| May 8, 2026 | Barclays | Maintained | Overweight | $48.00 |
| Apr 20, 2026 | Barclays | Upgraded | Underweight → Overweight | $45.00 |
| Mar 2, 2026 | Goldman Sachs | Maintained | Neutral | $34.00 |

## Frequently Asked Questions

### What is the price target for CLDX stock?

The average 12-month analyst price target for Celldex Therapeutics (CLDX) is $70.75, with a high estimate of $100.00 and a low of $53.00, across 8 analysts.

### Is CLDX a buy, sell, or hold?

Analysts covering Celldex Therapeutics currently average a Buy rating: 14 buy, 1 hold and 0 sell, from 15 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for CLDX?

The average price target of $70.75 implies 144.56% upside from the last price of $28.93.

### What is the latest analyst rating on CLDX?

On Oct 2, 2026, HC Wainwright & Co. maintained Celldex Therapeutics at Buy with a price target of $64.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).